DBV Technologies S.A. (DBVT)
NASDAQ: DBVT · Real-Time Price · USD
4.395
+0.145 (3.41%)
At close: Feb 21, 2025, 4:00 PM
4.400
+0.005 (0.11%)
After-hours: Feb 21, 2025, 4:08 PM EST
DBV Technologies Employees
As of December 31, 2023, DBV Technologies had 105 total employees, including 104 full-time and 1 part-time employees. The number of employees increased by 19 or 22.09% compared to the previous year.
Employees
105
Change (1Y)
19
Growth (1Y)
22.09%
Revenue / Employee
$119,190
Profits / Employee
-$972,276
Market Cap
85.42M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
DBVT News
- 5 weeks ago - Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - GlobeNewsWire
- 2 months ago - DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids - Benzinga
- 2 months ago - DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old - GlobeNewsWire
- 3 months ago - DBV Technologies Announces Plan to Implement ADS Ratio Change - GlobeNewsWire
- 3 months ago - DBV Technologies Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 4 months ago - DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe - GlobeNewsWire
- 4 months ago - DBV Technologies to Participate in Upcoming ACAAI 2024 Congress - GlobeNewsWire
- 5 months ago - DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial - GlobeNewsWire